Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor.

Boehringer has ended a decade of industrywide failures in idiopathic pulmonary fibrosis with a phase 3 win for a potentially first-in-class drug. [ABSTRACT FROM AUTHOR]